outperform price
guid issuanc similar
thesi updat beat st estimate comfort lsd revenue
declin come better peer similar revenue mix eg
declin hsd similar china exposur
investor nervou print thesi pki
higher dx exposur china impact lockdown
procedur delay instrument exposur revenue mix
manag round give revenue guid flat
declin similar guid
print manag confid busi model
highlight issuanc guid showcas portfolio
rev undergon past decad
transform highlight benefit covid
relat test solut contribut
nearli half come serolog done ton work
topic think pki test show specif
differenti high specif high ppv valu matter
reopen economi fals posit low
like pki prospect lastli margin execut
impress back impress
tight ar management rais pt equat
price-to-earnings reit outperform rate pt
multipl repres premium market multipl
ampli justifi given busi model resili
investor percept legaci need undergo
pleas see guid color market color
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
organ growth flat fx hw
expect life sci/reproduct health/appli genom fare better
non-covid product
increment covid-rel revenu
serolog remain rt pcr/ rna extract
apac dd
china y/i
da life strength off-set food appli soft
pharma/biotech hsd driven enterpris discoveri informat
discoveri screen research reagent enterpris servic dd
appli ldd
america hsd apac eu lsd
appli march order y/i
industrial/environmental/safeti ldd
food dd consum growth off-set instrument declin
come back china w/ safeti measur new way work
fund env hold rel well certain end mkt food/dx/lif
strength eu off-set apac weak china lsd
dx strength appli genom off-set declin immunodx/reproduct health
vital covid rt pcr workflow
led liquid handl nucleic acid extract
immunodx msd w/ euroimmun msd
immunodx almost china china rev growth us/eu
believ euroimmun includ mm stock
newborn test americas/eu hsd pre-stock
china reproduct health w/ newborn screen run util
believ reproduct health mm stock
growth americas/eu off-set dd declin china
reproduct health msd driven lower newborn prenat china
mm convers convers goal intact within next yr
covid net hw mm mm tw off-set mm hw
note cost structur highli variabl natur
rt pcr test run test month
euroimmun elisa test focus spike protein capac mm test month mm month soon
extract kit capac mm test month
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin may pm et
analyst luke sergott daniel markowitz cindi ding lilli shahidi vijay kumar primarili respons prepar research
report attest follow view opinion render research report reflect person view subject
compani issuer part research analyst compens directli relat specif
recommend view research report
